|
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
SHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large, prospective studies.
|
26666829 |
2015 |
|
Lymphoma, Non-Hodgkin
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our study suggests that variation in several OCM genes (CBS, FTHFD, SHMT1, TCN1, and TYMS) may influence susceptibility to NHL.
|
25384508 |
2015 |
|
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
A borderline significantly increased risk of NHL was also observed for CBS (rs1801181, Ex13+41C>T), FTHFD (rs2305230, Ex10-40G>T), SHMT1 (rs1979277, Ex12+138C>T), and SHMT1 (rs1979276, Ex12+236T>C), and these associations appeared to be contingent on dietary nutrient intakes.
|
23913011 |
2013 |
|
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Meta-analysis for SNPs in the MTHFR, MTR, MTRR and SHMT revealed a reducing effect of the MTR 2756G allele on the risk of NHL (OR=0.902; 95% CI 0.821-0.991, P=0.03).
|
21055808 |
2011 |
|
Lymphoma, Non-Hodgkin
|
0.350 |
Biomarker
|
disease |
CTD_human |
We observed a decreased risk of NHL over-all with BHMTEx8+453A>T and increased risk with CBS Ex13+41C>T, FPGS Ex15-263T>C, and SHMT1 Ex12+138C>T and Ex12+236C>T.
|
17119116 |
2007 |
|
Lymphoma, Non-Hodgkin
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
The polymorphisms examined and haplotypes generated included thymidylate synthase (TYMS 28-bp triple repeat [3R]-->double repeat [2R], 1494del6, IVS6 -68C>T, 1122A>G, and 1053C>T); 5,10-methylenetetrahydrofolate reductase (MTHFR 677C>T and 1298A>C); serine hydroxymethyltransferase (SHMT1 C1420T); reduced folate carrier (RFC G80A); and methionine synthase (MTR A2756G), making the present study the largest and most comprehensive to date to evaluate associations between genetic polymorphisms in folatemetabolizing genes and NHL risk.
|
15198953 |
2004 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggested that the SHMT1 C1420T polymorphism was associated with decreased risk of breast cancer.
|
26125758 |
2015 |
|
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Therefore, our meta-analysis suggested that the SHMT1 C1420T polymorphism was associated with decreased risk of breast cancer.
|
26125758 |
2015 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In the subgroup analysis based on ethnicity, SHMT1 C1420T polymorphism has shown a protective effect on breast cancer in Asians (T vs. C, OR = 0.78, 95 % CI = 0.66-0.93) but not in Caucasian (T/T vs. C/C, OR = 0.98, 95 % CI = 0.86-1.12).
|
24789272 |
2014 |
|
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
In the subgroup analysis based on ethnicity, SHMT1 C1420T polymorphism has shown a protective effect on breast cancer in Asians (T vs. C, OR = 0.78, 95 % CI = 0.66-0.93) but not in Caucasian (T/T vs. C/C, OR = 0.98, 95 % CI = 0.86-1.12).
|
24789272 |
2014 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
|
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
Conversely, for women over 50, the risk of breast cancer development was statistically associated with the MTHFR 677CT genotype, but especially significant was risk associated with the presence of the polymorphic allele of cSHMT C1420T (P = 0.0120) and the protective effect associated with the RFC1 G80A polymorphism allele (P = 0.0021), was restrict to this age group.
|
22134752 |
2012 |
|
Malignant neoplasm of breast
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.
|
19707223 |
2010 |
|
Breast Carcinoma
|
0.340 |
GeneticVariation
|
disease |
BEFREE |
There was no evidence of an association between the cSHMT genotype and breast cancer occurrence.
|
19707223 |
2010 |
|
Malignant neoplasm of breast
|
0.340 |
Biomarker
|
disease |
CTD_human |
Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan.
|
17595805 |
2007 |
|
Breast Carcinoma
|
0.340 |
Biomarker
|
disease |
CTD_human |
Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan.
|
17595805 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
miR-218-5p was enhanced and SHMT1 was inhibited in NK cells of LA patients, whereas stimulation of interleukin-2 (IL-2) reversed their abundances.
|
31124332 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
In conclusion, we demonstrate that hsa_circ_0025036 regulates cell proliferation and apoptosis in lung adenocarcinoma cells probably via hsa_circ_0025036/miR-198/SHMT1&TGF-α axis. hsa_circ_0025036 may serve as a potential prognostic biomarker and a therapeutic target for lung adenocarcinoma.
|
30138108 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
BEFREE |
In conclusion, miR-198 suppressed proliferation of lung adenocarcinoma cells both in vitro and in vivo by directly targeting SHMT1. miR-198 may be a potential therapeutic target for lung adenocarcinoma in the near future.
|
26553359 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.330 |
Biomarker
|
disease |
CTD_human |
c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma.
|
27602772 |
2016 |
|
Mammary Neoplasms
|
0.320 |
GeneticVariation
|
group |
LHGDN |
Polymorphism of cytosolic serine hydroxymethyltransferase, estrogen and breast cancer risk among Chinese women in Taiwan.
|
17896178 |
2008 |
|
Mammary Neoplasms
|
0.320 |
Biomarker
|
group |
CTD_human |
Breast cancer risk associated with multigenotypic polymorphisms in folate-metabolizing genes: a nested case-control study in Taiwan.
|
17595805 |
2007 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
LHGDN |
Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients.
|
16049973 |
2006 |
|
Lymphoma, Non-Hodgkin, Familial
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
SHMT1 C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients.
|
26666829 |
2015 |
|
Schizophrenia
|
0.310 |
Biomarker
|
disease |
PSYGENET |
These results suggest that Shmt1 (SHMT1), but not Srr, is likely to be one of the genetic components regulating PPI in mice and possibly relevant to schizophrenia.
|
20977478 |
2010 |